GAD1 and Onset: Of note, GAD-Alum (Diamyd Therapeutics) has been evaluated in several Phase I and II trials with anti-GAD65 antibody positive (Stage 2) or new-onset (Stage 3) subjects and showed trends toward preservation of residual insulin secretion, especially in subjects with late-onset autoimmune diabetes of adulthood (LADA) [27], but failed this trend in Phase III trials [32,33].